→ Defy New Year’s instability with artificial intelligence (From Vantage Point)
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) – HC Wainwright analysts provide 2027 EPS estimates for Compass Therapeutics shares in a research note issued to investors on Wednesday, January 18 Did. HC Wainwright analyst J. Pantginis expects the company’s annual earnings to be $0.01 per share. HC Wainwright is rated Buy with a price target of $10.00. Compass Therapeutics’ current consensus estimate for annual earnings is $0.39 per share.
Compass Therapeutics (NASDAQ:CMPX – Get Rating) last reported quarterly results on Wednesday, November 9th. The company reported his earnings per share (EPS) for the quarter ($0.12), missing consensus expectations ($0.11) ($0.01).
Several other research firms have also recently published reports on CMPX. LADENBURG THALM/SH SH raised his price target on Compass Therapeutics stock to his $9.00 in a research note on Wednesday, November 16th. Raymond James raised Compass Therapeutics’ stock price target from his $5.00 to his $8.00 in a research report on Thursday, Nov. 10, giving the stock an “outperform” rating. Finally, EF Hutton Acquisition Co. I featured his Compass Therapeutics stake in a research report on Friday, Dec. 16. They set a Buy rating and set a company price target of $10.30. According to MarketBeat.com, Compass Therapeutics currently has an average Buy rating with a consensus target price of $9.33.
Compass Therapeutics Stock Performance
CMPX shares opened at $3.85 on Friday. The company has a 50-day moving average price of $4.74 and a 200-day moving average price of $3.55. The company has a market capitalization of $485.84 million, a P/E ratio of -8.93 and a beta of 1.35. Compass Therapeutics has a 52-week low of $1.25 and a 52-week high of $5.65.
In another Compass Therapeutics news, COO Vered Bisker-Leib sold 14,929 shares in the company in a transaction on Tuesday, November 22nd. The shares sold for an average of $4.19 for a total of $62,552.51. Following the closing of the sale, the Chief Operating Officer now directly owns his 1,069,985 shares in the company, valued at $4,483,237.15. The transaction was disclosed in filings with the Securities and Exchange Commission and is available on his website at the SEC. In separate news, his COO Vered Bisker-Leib sold 14,929 shares of Compass Therapeutics in a deal on Tuesday, Nov. 22. The shares sold at an average price of $4.19, and the transaction totaled him $62,552.51. Following the closing of the transaction, the Chief Operating Officer now owns directly his 1,069,985 shares in the company, valued at his $4,483,237.15. The sale was disclosed in filings with the Securities and Exchange Commission, which can be accessed at this link. The director of Orbimed Advisors Llc also said he acquired 402,000 shares of Compass Therapeutics in a transaction on Tuesday, November 8th. The shares were acquired at an average price of $3.21 per share and an aggregate value of $1,290,420.00. Following the completion of the acquisition, the directors now directly own 15,219,994 shares of the Company’s stock valued at $48,856,180.74. For disclosure of this purchase, please click here. A corporate insider owns his 29.80% of the company’s shares.
institution inflow and outflow
Many large investors have recently changed positions in the company. Flagship Harbor Advisors LLC purchased new shares of Compass Therapeutics in the second quarter for a value of approximately $37,000. Jane Street Group LLC purchased a new stake in his Compass Therapeutics worth approximately $33,000 in the third quarter. The Bank of New York Mellon Corp bought a new stake in his Compass Therapeutics worth about $55,000 in the third quarter. Marshall Wace LLP increased his position in Compass Therapeutics by 118.4% in the third quarter. Marshall Weiss LLP now owns 51,816 shares of the company, valued at $117,000, after acquiring an additional 28,089 shares during this period. Finally, Renaissance Technologies LLC increased its position in Compass Therapeutics by 397.5% in the second quarter. Renaissance Technologies LLC now owns 66,165 shares of the company stock valued at $175,000 after acquiring an additional 52,865 shares during this period. 54.27% of the shares are owned by institutional investors.
Compass Therapeutics Company Profile
Compass Therapeutics, Inc. is a biopharmaceutical company focused on clinical-stage oncology, working to develop antibody-based therapeutics to treat a variety of human diseases. The Company’s product candidates in clinical development include CTX-009, an investigational bispecific antibody that blocks the delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways. CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to email@example.com.
Listen to this before considering Compass Therapeutics.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified 5 stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Compass Therapeutics wasn’t on the list .
Compass Therapeutics is currently rated as a ‘buy’ among analysts, but the top rated analysts believe these five stocks are better buys.
See 5 stocks here